Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2007 1
2008 2
2009 1
2010 1
2011 1
2013 1
2014 2
2015 3
2016 1
2017 1
2018 3
2019 7
2020 9
2021 10
2022 13
2023 6
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial.
Jagsi R, Barlow WE, Woodward WA, Connolly E, Mahtani R, Shumway D, Speers C, Stecklein SR, Zeidan Y, Zhang H, Sharma P, Pusztai L, Hortobagyi GN, Kalinsky K. Jagsi R, et al. Among authors: mahtani r. JAMA Oncol. 2023 Aug 1;9(8):1083-1089. doi: 10.1001/jamaoncol.2023.1984. JAMA Oncol. 2023. PMID: 37410451 Free PMC article. Clinical Trial.
Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2.
Gelmon K, Walshe JM, Mahtani R, Joy AA, Karuturi M, Neven P, Lu DR, Kim S, Schnell P, Bananis E, Schwartzberg L. Gelmon K, et al. Among authors: mahtani r. Breast. 2021 Oct;59:321-326. doi: 10.1016/j.breast.2021.07.017. Epub 2021 Jul 28. Breast. 2021. PMID: 34388698 Free PMC article. Clinical Trial.
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Shen F, Storniolo AMV, Badve S, Ballinger TJ, Chang CL, Zhong Y, Savran C, Miller KD, Schneider BP. Radovich M, et al. Among authors: mahtani r. JAMA Oncol. 2020 Sep 1;6(9):1410-1415. doi: 10.1001/jamaoncol.2020.2295. JAMA Oncol. 2020. PMID: 32644110 Free PMC article. Clinical Trial.
When Can a Salvage Therapy (T-DM1) Take the Lead?
Mahtani RL, Vogel CL. Mahtani RL, et al. J Clin Oncol. 2016 Oct 10;34(29):3492-3494. doi: 10.1200/JCO.2016.68.4241. J Clin Oncol. 2016. PMID: 27432926 No abstract available.
Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
Mahtani R, Kittaneh M, Kalinsky K, Mamounas E, Badve S, Vogel C, Lower E, Schwartzberg L, Pegram M; Breast Cancer Therapy Expert Group (BCTEG). Mahtani R, et al. Clin Breast Cancer. 2021 Oct;21(5):383-390. doi: 10.1016/j.clbc.2020.12.011. Epub 2020 Dec 29. Clin Breast Cancer. 2021. PMID: 33781662 Review.
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, Cristofanilli M, Meisel J, Miller KD, Abdou Y, Riley EC, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block CC, Ko N, Partridge AH, Chen WY, DeMeo M, Attaya V, Okpoebo A, Alberti J, Liu Y, Gauthier E, Burstein HJ, Regan MM, Tolaney SM. Mayer EL, et al. Among authors: mahtani r. J Clin Oncol. 2024 Jun 10;42(17):2050-2060. doi: 10.1200/JCO.23.01940. Epub 2024 Mar 21. J Clin Oncol. 2024. PMID: 38513188 Clinical Trial.
61 results